X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q3 2025 results and a corporate update focused on advancing the 4WARD Phase 3 trial of mavorixafor for chronic neutropenia. The company completed two financings totaling $240.3M and said cash runway now extends to the end of 2028, supporting trial completion, a potential sNDA filing and a possible 2028 launch if successful. Operational changes include a 50% workforce reduction (estimated $13M annualized savings), deprioritization of WHIM commercialization, promotion of John Volpone to COO, and an increased 4WARD enrollment target of 176 patients with completion expected in Q3 2026.
Q3 net product sales were $1.6M, Q3 net loss was $29.8M (EPS -$0.69), and cash, cash equivalents and short-term investments were $122.2M as of Sept 30, 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) ha riportato i risultati del terzo trimestre 2025 e un aggiornamento aziendale focalizzato sul progresso del 4WARD Phase 3 trial di mavorixafor per la neutropenia cronica. L'azienda ha completato due finanziamenti per un totale di $240.3M e ha dichiarato che la runway di cassa si estende ora fino alla fine del 2028, supportando il completamento dello studio, un'eventuale richiesta sNDA e un possibile lancio nel 2028 se avrà successo. Le modifiche operative includono una riduzione del 50% del personale (risparmi annualizzati stimati $13M), la deprioritizzazione della commercializzazione WHIM, la promozione di John Volpone a COO e un aumento dell'obiettivo di reclutamento per il 4WARD a 176 pazienti con completamento previsto nel Q3 2026.
I ricavi netti del Q3 da prodotto erano $1.6M, la perdita netta del Q3 era $29.8M (EPS -$0.69), e la cassa, equivalenti di cassa e investimenti a breve termine erano $122.2M al 30 settembre 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) informó resultados del 3T 2025 y una actualización corporativa centrada en avanzar en el ensayo 4WARD Phase 3 de mavorixafor para neutropenia crónica. La empresa completó dos financiamientos por un total de $240.3M y afirmó que la reserva de efectivo se extiende ahora hasta el final de 2028, apoyando la finalización del ensayo, una potencial presentación de sNDA y un posible lanzamiento en 2028 si tiene éxito. Los cambios operativos incluyen una reducción de plantilla del 50% (ahorros anuales estimados de $13M), la despriorización de la comercialización de WHIM, la promoción de John Volpone a COO y un aumento del objetivo de reclutamiento del 4WARD a 176 pacientes con finalización prevista en Q3 2026.
Las ventas netas de productos en el 3T fueron $1.6M, la pérdida neta del 3T fue $29.8M (EPS -$0.69), y el efectivo, equivalentes de efectivo y inversiones a corto plazo eran $122.2M a 30 de septiembre de 2025.
X4 Pharmaceuticals (Nasdaq: XFOR)는 2025년 3분기 실적과 4WARD Phase 3의 mavorixafor를 통한 만성 호중구감소증 치료를 중심으로 한 기업 업데이트를 발표했습니다. 회사는 총 $240.3M의 두 차례 자금 조달을 완료했고 현금 잔여 기간이 이제 2028년 말까지 연장되어 연구 완료, sNDA 제출 가능성, 성공 시 2028년 출시의 가능성을 뒷받침합니다. 운영 변화로는 직원 50%의 감축(연간 예상 절감 $13M), WHIM 상용화의 우선순위 축소, John Volpone를 COO로 승진, 4WARD 등록 목표를 176명으로 상향, 완료 예정을 2026년 3분기로 설정했습니다.
3분기 순제품 매출은 $1.6M, 3분기 순손실은 $29.8M (EPS -$0.69), 현금 및 현금등가물과 단기투자는 2025년 9월 30일 기준 $122.2M였습니다.
X4 Pharmaceuticals (Nasdaq: XFOR) a publié les résultats du T3 2025 et une mise à jour corporate axée sur l'avancement du essai 4WARD Phase 3 de mavorixafor pour la neutropénie chronique. L'entreprise a finalisé deux financements pour un total de $240.3M et a déclaré que la runway de trésorerie s'étend désormais jusqu'à fin 2028, soutenant l'achèvement de l'essai, une éventuelle demande d sNDA et un possible lancement en 2028 si le succès est au rendez-vous. Les changements opérationnels incluent une réduction de 50% des effectifs (économies annuelles estimées à $13M), la dépriorisation de la commercialisation de WHIM, la promotion de John Volpone au poste de COO et un objectif d'inscription au 4WARD porté à 176 patients avec une achèvement prévu pour Q3 2026.
Les ventes nettes de produits au T3 étaient $1.6M, la perte nette du T3 était $29.8M (EPS -$0.69), et la trésorerie, les équivalents de trésorerie et les investissements à court terme s'élevaient à $122.2M au 30 septembre 2025.
X4 Pharmaceuticals (Nasdaq: XFOR) berichtete über die Ergebnisse des 3. Quartals 2025 und ein Unternehmensupdate mit Fokus auf die Fortführung der 4WARD Phase 3-Studie von Mavorixafor zur chronischen Neutropenie. Das Unternehmen schloss zwei Finanzierungen über insgesamt $240.3M ab und gab an, dass die Barreserve jetzt bis zum Ende 2028 reicht, um den Abschluss der Studie, eine mögliche sNDA-Anmeldung und eine mögliche Markteinführung im Jahr 2028 zu unterstützen, falls erfolgreich. Zu den operativen Änderungen gehört eine 50%-Reduzierung der Belegschaft (geschätzte jährliche Einsparungen von $13M), die Abpriorisierung der WHIM-Kommerzialisierung, die Beförderung von John Volpone zum COO und eine erhöhte Rekrutierungszielung für das 4WARD auf 176 Patienten mit einem Abschluss geplant für Q3 2026.
Der Nettoumsatz aus Produkten im Q3 betrug $1.6M, der Nettoverlust im Q3 betrug $29.8M (EPS -$0.69), und Bargeld, Zahlungsmitteläquivalente und kurzfristige Investitionen beliefen sich zum 30. Sept. 2025 auf $122.2M.
X4 Pharmaceuticals (Nasdaq: XFOR) أبلغت عن نتائج الربع الثالث من 2025 وتحديثاً تنفيذيّاً يركز على تقدم تجربة 4WARD Phase 3 من مافوريكسافور لعلاج نقص المحببات المزمن. أكملت الشركة تمويلاًين بإجمالي $240.3M وقالت إن مدى النقد المتاح يمتد حتى نهاية 2028، وهو ما يدعم إتمام الدراسة، وتقديم sNDA محتمل وإطلاق محتمل في 2028 إذا كان ناجحاً. تشمل التغييرات التشغيلية خفضاً بنسبة 50% في القوة العاملة (وفورات سنوية تقديرية تبلغ $13M)، تقليل الأولوية لتسويق WHIM، ترقية جون فولوپوني إلى COO، وزيادة هدف التسجيل في 4WARD إلى 176 مريضاً مع توقع الإنهاء في الربع الثالث 2026.
بلغت مبيعات المنتجات الصافية في الربع الثالث $1.6M، وكانت الخسارة الصافية للربع الثالث $29.8M (EPS -$0.69)، وكانت النقدية وما يعادلها والاستثمارات قصيرة الأجل $122.2M حتى 30 سبتمبر 2025.
- Two financings totaling $240.3M closed in 2025
- Cash runway extended to end of 2028
- 4WARD enrollment target increased to 176 patients
- Annualized cost savings of approximately $13M from workforce reduction
- Q3 2025 net loss of $29.8M (EPS -$0.69)
- Nine-month operating loss of $63.2M through Sept 30, 2025
- Net income in prior year turned to a $55.3M loss year-to-date
- Low Q3 product sales of $1.6M in the US
Insights
X4 secured funding and extended runway to end of
X4 Pharmaceuticals shifted corporate priority to complete the 4WARD Phase 3 pivotal trial of mavorixafor in moderate and severe chronic neutropenia, increased enrollment to 176 patients, and now expects enrollment complete in
The strengthened cash position and stated runway to the end of
Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial
Previously announced workforce reductions resulted in
Successful completion of two financial transactions totaling
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results for the third quarter ended September 30, 2025 and provided a corporate update.
“The third quarter of 2025 was a time of corporate restructuring at X4 with the start of a new leadership team and a renewed focus on chronic neutropenia,” said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. “With a strengthened financial position through two successful financings totaling
Recent Accomplishments and Updates
- Since early August, the Company has initiated a number of measures to restructure its operations:
- A shift in the primary focus of the Company to the successful completion of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia.
- A deprioritization of the commercialization of mavorixafor (XOLREMDI) for patients with WHIM syndrome, while maintaining patient access.
- A
50% reduction in the workforce (expected to generate approximately$13 million in annualized cost savings) with continued cost cutting measures. - An increase in the enrollment target for the pivotal Phase 3 4WARD study to 176 patients with enrollment now expected to be completed in third quarter of 2026.
- The promotion of John Volpone to the role of Chief Operating Officer, in addition to his responsibilities as President.
- Dr. Adam Craig expanded his role to include oversight of clinical development activities.
- Since August, the Company raised
$240.3 million in gross proceeds from two successful financings: the closing of a$155.3 million underwritten public offering and an$85 million upsized private placement. - With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028.
Third-Quarter and Recent 2025 Financial Results
Net product sales of
Net loss for the three months ended September 30, 2025 was
Cash, cash equivalents and short-term investments totaled
About Chronic Neutropenia and Mavorixafor
Chronic neutropenia is a primary, rare blood condition lasting more than three months, persistently or intermittently, and characterized by low levels of circulating neutrophils and increased risk of serious and life-threatening infections and reduced quality of life due to abnormally low levels of neutrophils circulating in the blood. Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells. Downregulation of the CXCR4 receptor by mavorixafor, an orally active CXCR4 antagonist, has been shown to mobilize functional neutrophils from the bone marrow into the peripheral blood across multiple disease states. The level of circulating neutrophils is typically measured by drawing blood to determine the absolute neutrophil count (ANC).
About the 4WARD Clinical Trial
The 4WARD trial is a global, pivotal Phase 3 clinical trial (NCT06056297) evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 176 patients with confirmed trough ANC levels less than 1,000 cells per microliter at baseline screening and histories of two or more serious and/or recurrent infections in the prior year. The primary endpoints of the study are the reduction in annualized infection rate and positive ANC response.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the expected cost savings from the workforce reduction, the expected results of the restructuring of business operations, the sufficiency of the Company’s cash resources and its expected cash runway, the potential addressable market for moderate and severe chronic neutropenia, the timing for launch of mavorixafor and future plans for the Company. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: the workforce reduction does not result in the anticipated cost savings described herein; the results of the restructuring of business operations are not as anticipated; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on X4’s Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its quarterly report on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.
X4 Investor Contact:
IR@X4pharma.com
| (Tables Follow) |
| X4 PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| License and other revenue | $ | 199 | $ | — | $ | 28,293 | $ | — | ||||||||
| Product revenue, net | 1,566 | 560 | 4,252 | 1,123 | ||||||||||||
| Total revenue | 1,765 | 560 | 32,545 | 1,123 | ||||||||||||
| Costs and operating expenses: | ||||||||||||||||
| Cost of revenue | 351 | 227 | 5,393 | 495 | ||||||||||||
| Research and development | 17,337 | 19,173 | 54,202 | 59,941 | ||||||||||||
| Selling, general and administrative | 11,586 | 15,660 | 36,134 | 46,373 | ||||||||||||
| Gain on sale of non-financial asset | — | — | — | (105,000 | ) | |||||||||||
| Total operating expenses | 29,274 | 35,060 | 95,729 | 1,809 | ||||||||||||
| Loss from operations | (27,509 | ) | (34,500 | ) | (63,184 | ) | (686 | ) | ||||||||
| Other income, net | (2,336 | ) | (2,181 | ) | 7,951 | 3,109 | ||||||||||
| (Loss) income before provision for income taxes | (29,845 | ) | (36,681 | ) | (55,233 | ) | 2,423 | |||||||||
| Provision for income taxes | (30 | ) | 15 | 41 | 52 | |||||||||||
| Net (loss) income | $ | (29,815 | ) | $ | (36,696 | ) | $ | (55,274 | ) | $ | 2,371 | |||||
| Net (loss) income per share- basic. | $ | (0.69 | ) | $ | (5.48 | ) | $ | (2.87 | ) | $ | 0.35 | |||||
| Weighted average shares outstanding-basic | 43,273 | 6,696 | 19,243 | 6,681 | ||||||||||||
| Net (loss) income per share- diluted | $ | (0.69 | ) | $ | (5.48 | ) | $ | (2.87 | ) | $ | 0.35 | |||||
| Weighted average shares outstanding-diluted | 43,273 | 6,696 | 19,243 | 6,687 | ||||||||||||
Balance Sheet Data (unaudited)
| (amounts in thousands) | ||||||
| September 30, 2025 | December 31, 2024 | |||||
| Cash and cash equivalents | $ | 69,632 | $ | 55,699 | ||
| Accounts receivable | 891 | 1,070 | ||||
| Marketable securities | 52,562 | 46,361 | ||||
| Working capital | 109,299 | 79,298 | ||||
| Total assets | 163,555 | 146,447 | ||||
| Current portion of long-term debt | — | — | ||||
| Total stockholders' equity | 61,619 | 22,149 | ||||
FAQ
What did X4 Pharmaceuticals (XFOR) announce on November 5, 2025 regarding the 4WARD Phase 3 trial?
How much funding did XFOR raise in 2025 and what is the cash runway?
What were XFOR's Q3 2025 financial highlights including net loss and product sales?
What cost reductions did X4 Pharmaceuticals (XFOR) implement in 2025?
Will XFOR pursue commercial launch for mavorixafor in chronic neutropenia and by when?
How does X4 plan to handle WHIM syndrome commercialization after the restructuring?
